MA54549A - Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih - Google Patents

Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih

Info

Publication number
MA54549A
MA54549A MA054549A MA54549A MA54549A MA 54549 A MA54549 A MA 54549A MA 054549 A MA054549 A MA 054549A MA 54549 A MA54549 A MA 54549A MA 54549 A MA54549 A MA 54549A
Authority
MA
Morocco
Prior art keywords
infected cells
cytotoxic agents
against hiv
agents against
pyrimidone derivatives
Prior art date
Application number
MA054549A
Other languages
English (en)
Inventor
Antonella Converso
Marrouni Abdellatif El
Ashley Forster
Jessica L Frie
David N Hunter
Scott D Kuduk
Helen J Mitchell
Philippe Nantermet
Deyou Sha
William Daniel Shipe
Cheng Wang
Deping Wang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA54549A publication Critical patent/MA54549A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA054549A 2018-12-18 2019-12-13 Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih MA54549A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862781356P 2018-12-18 2018-12-18

Publications (1)

Publication Number Publication Date
MA54549A true MA54549A (fr) 2022-03-30

Family

ID=69411500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054549A MA54549A (fr) 2018-12-18 2019-12-13 Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih

Country Status (25)

Country Link
US (1) US12258329B2 (fr)
EP (1) EP3898595B1 (fr)
JP (1) JP7045528B2 (fr)
KR (1) KR102645602B1 (fr)
CN (1) CN113423695A (fr)
AR (1) AR119126A1 (fr)
AU (1) AU2019402998B2 (fr)
BR (1) BR112021011733A8 (fr)
CA (1) CA3122571C (fr)
CL (2) CL2021001514A1 (fr)
CO (1) CO2021007667A2 (fr)
CR (1) CR20210317A (fr)
DO (1) DOP2021000129A (fr)
EA (1) EA202191711A1 (fr)
EC (1) ECSP21043491A (fr)
IL (1) IL283821A (fr)
JO (1) JOP20210149A1 (fr)
MA (1) MA54549A (fr)
MX (1) MX2021007382A (fr)
NI (1) NI202100048A (fr)
PE (1) PE20211704A1 (fr)
PH (1) PH12021551408A1 (fr)
SG (1) SG11202106310YA (fr)
TW (1) TW202122384A (fr)
WO (1) WO2020131597A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
AU2020279954B2 (en) * 2019-05-22 2025-11-13 Merck Sharp & Dohme Llc Pyridinone derivatives as selective cytotoxic agents against HIV infected cells
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
US12133620B2 (en) 2022-02-11 2024-11-05 Whirlpool Corporation Dishwasher with direct water supply
CN116217493A (zh) * 2023-02-07 2023-06-06 郑州猫眼农业科技有限公司 一种4,6-二氯-2-甲基-5-嘧啶甲醛的制备方法
WO2025193566A1 (fr) * 2024-03-15 2025-09-18 Merck Sharp & Dohme Llc Dérivés de n-oxyde utilisés en tant qu'agents cytotoxiques sélectifs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20003978A3 (cs) * 1998-04-27 2001-09-12 Centre National De La Recherche Scientifique Deriváty 3-(amino- nebo aminoalkyl) pyridinonu a jejich použití
WO2004085406A1 (fr) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinones en tant qu'inhibiteurs de transcriptase inverse
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
BRPI0811645A2 (pt) 2007-05-30 2014-11-11 Hoffmann La Roche Inibidores de transcriptase reversa de não-nucleosídeo
CN101952274A (zh) 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
MX2012011379A (es) 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
SI3125894T1 (sl) * 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
EP3669876A1 (fr) 2018-12-18 2020-06-24 Aelis Farma 3béta- (benzyloxy)-17alpha-méthyl-pregn-5-en-20-one pour une utilisation dans le traitement de troubles cognitifs
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.

Also Published As

Publication number Publication date
CA3122571C (fr) 2023-08-01
EA202191711A1 (ru) 2021-10-04
US20220064147A1 (en) 2022-03-03
TW202122384A (zh) 2021-06-16
PH12021551408A1 (en) 2022-05-16
MX2021007382A (es) 2021-07-15
JP7045528B2 (ja) 2022-03-31
IL283821A (en) 2021-07-29
BR112021011733A8 (pt) 2023-04-18
PE20211704A1 (es) 2021-09-01
JOP20210149A1 (ar) 2023-01-30
JP2022508380A (ja) 2022-01-19
KR102645602B1 (ko) 2024-03-07
EP3898595B1 (fr) 2024-05-01
KR20210104796A (ko) 2021-08-25
CN113423695A (zh) 2021-09-21
NI202100048A (es) 2021-08-09
EP3898595A1 (fr) 2021-10-27
AU2019402998A1 (en) 2021-06-24
AR119126A1 (es) 2021-11-24
ECSP21043491A (es) 2021-07-30
CO2021007667A2 (es) 2021-07-19
CR20210317A (es) 2021-07-14
BR112021011733A2 (pt) 2021-08-31
AU2019402998B2 (en) 2022-12-15
DOP2021000129A (es) 2021-08-15
CA3122571A1 (fr) 2020-06-25
WO2020131597A1 (fr) 2020-06-25
CL2022000659A1 (es) 2022-10-28
US12258329B2 (en) 2025-03-25
CL2021001514A1 (es) 2021-11-26
SG11202106310YA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
EP3784665A4 (fr) Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
IL283821A (en) Pyrimidone derivatives as selective cytotoxic agents against hiv-infected cells
MA51629A (fr) Procédés de production, purification et formulation de conjugués anticorps-médicaments
MA52940A (fr) Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA55804A (fr) Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
MA47231A (fr) Conjugués anticorps-médicament pour l'ablation de cellules souches hématopoïétiques
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MX387596B (es) Degradadores selectivos del receptor de estrógeno y sus usos.
MD3313851T2 (ro) Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin
EA201790446A1 (ru) Цитотоксические бензодиазепиновые производные
MA39809A (fr) Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih
EP3921319A4 (fr) Dérivés imidazo [2, 1-f] [1, 2, 4] triazin-4-amine en tant qu'agonistes de tlr7
MA44502A (fr) Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
EP3377066A4 (fr) Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
PH12018500071A1 (en) Plinabulin compositions
EP3402793A4 (fr) Dérivés de pyridazine en tant qu'activateurs d'eaat2
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
EP3724162A4 (fr) Intermédiaires pour des dérivés de pipéridine optiquement actifs et leurs procédés de préparation
EP3679042A4 (fr) Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
MA54228A (fr) Procédés de préparation de dérivés de benzodiazépine cytotoxiques